917737
NanoFabTx™ materials screening kit
for synthesis of polymeric nanoparticles
Synonym(s):
Non-PEGylated drug delivery formulation, PCL, PLA, PLGA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12161503
NACRES:
NA.23
Recommended Products
description
Kit components :
PLGA-Nano (907782-500mg)
PLGA-Nano75 (916382-500mg)
PLA-Nano (910996-500mg)
PCL-Nano (916382-500mg)
Stabilizer - P (913448-10g)
Quality Level
application(s)
advanced drug delivery
General description
NanoFabTx™ formulation kits and lipid mixes enable users to encapsulate a wide variety of therapeutic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx™ kits provide an easy to use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery and vaccine delivery.
Application
The NanoFabTx™ materials screening kit, for synthesis of polymeric nanoparticles, is a ready-to-use nanoformulation kit for the synthesis of nanoparticles for drug delivery. Poly(lactic-co-glycolic acid) (PLGA), poly(D,L-lactic acid) (PLA) and polycaprolactone (PCL) are biocompatible and biodegradable polymers that have been approved by the FDA for biomedical and pharmaceutical applications. This kit includes properly selected PLGA, PLA, and PCL polymers and stabilizer, allowing for rapid screening of optimal materials for enhanced drug loading and controlled drug release.
Features and Benefits
- Ready-to-use polymer drug formulation screening kit for non-PEGylated nanoparticles
- Choose from either nanopreciptiation or microfluidics-based protocols
- Create specifically sized, biodegradable, PLGA, PLA, or PCL nanoparticles
- Maximize the encapsulation of hydrophobic drugs
- Four different non-PEGylated polymers are included
Preparation Note
Comprehensive protocols for nanoparticle synthesis methods are included:
The microfluidics protocol uses NanoFabTx™ device kits (911593), which provide the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).
For more information, please refer to the protocol under the document section of this page.
- A nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
- A microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx™ device kits (911593), which provide the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).
For more information, please refer to the protocol under the document section of this page.
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
Robert F Pagels et al.
Journal of controlled release : official journal of the Controlled Release Society, 219, 519-535 (2015-09-12)
Biologically derived therapeutics, or biologics, are the most rapidly growing segment of the pharmaceutical marketplace. However, there are still unmet needs in improving the delivery of biologics. Injectable polymeric nanoparticles and microparticles capable of releasing proteins and peptides over time
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices
Byung Kook Lee et al.
Advanced drug delivery reviews, 107, 176-191 (2016-06-06)
Poly(d,l-lactic acid) (PLA) has been widely used for various biomedical applications for its biodegradable, biocompatible, and nontoxic properties. Various methods, such as emulsion, salting out, and precipitation, have been used to make better PLA micro- and nano-particle formulations. They are
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service